Tax rulings make U.S. less attractive for Canadian companies

A recent ruling by the U.S. Treasury Department scuttled a proposed and very large merger between two drug companies—the U.S.-based Pfizer Corporation and the Dublin-based Allergan. The proposed merger was motivated in part by expected tax savings that would have been realized by Pfizer moving its headquarters to Ireland after

Vist The Fraser Institute to read the complete article